Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Amgen (NASDAQ: AMGN ) will present at ... Thursday, May 30, 2013, at the Westin Boston Waterfront Hotel, ... Daylight Time. Arvind Sood , vice president ... Live audio of the presentation can be accessed from the ... A replay of the webcast will also be available on ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
(Date:5/23/2013)... , May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... medical technology company, today scheduled a conference call to ... fiscal year 2013, ended April 30, 2013. The call ... 30, 2013. The Company will report financial results for ... markets close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... 2011 AdvaMed 2011: The MedTech Conference ... 90 exhibitors including Abbott, Abiomed, B. Braun Medical, ... Johnson, KCI, and MIT MEDRC in Innovation Alley, ... diagnostic technologies. Three sector meet-ups focused on orthopedic, ...
... 28, 2011 Dynatronics Corporation (NASDAQ: DYNT ) today ... 30, 2011. Sales for the quarter ended June 30, ... quarter ended June 30, 2010. Sales for the year ended June ... for the prior year. Net income for the ...
Cached Medicine Technology:AdvaMed 2011: The MedTech Conference Closing Day Features Life Changing Innovation, Policymaker Addresses 2Dynatronics Announces Fourth Quarter and Year-end Results 2Dynatronics Announces Fourth Quarter and Year-end Results 3Dynatronics Announces Fourth Quarter and Year-end Results 4
(Date:5/24/2013)... 24, 2013 E-Dentists.com has announced the ... with JD Media Surge, a leading medical Internet marketing ... SEO analysis service will focus on providing dentists the ... engines for their competitive keywords. The dental SEO analysis ... recommendations based on what their competitors are doing right. ...
(Date:5/24/2013)... 24, 2013 Started in 1982, AMTC’s SHINE ... Orlando. 2013 marks AMTC’s 31st anniversary. SHINE is a ministry ... supermodel Millie Lewis and her daughter, Carey Lewis Arban. , ... casting directors, and music professionals including the New York Film ... Media. They are kings of Hollywood and Christian casting directors. ...
(Date:5/24/2013)... Utah (PRWEB) May 24, 2013 Amirsys ... with exciting new enhancements for instructors and students. Instructors ... more focused through personalize learning plan templates, targeted reading ... release provides 500 new assessment questions, 5,000 searchable anatomy ... notes. , AnatomyOne 2.0 is the first ...
(Date:5/24/2013)... Dwell Media LLC announces the ... Vice President of Digital for Dwell Media. At Yahoo, ... large portion of Yahoo's global media business. At Dwell, ... fully-integrated commerce unit to launch in 2014. Huff brings ... for leading firms in Silicon Valley. Dwell, which has ...
(Date:5/24/2013)... minority parents have more realistic views about their ... vaccinating their daughters against the cervical cancer-causing human ... Conversely, white, middle-class parents are more likely to ... researchers from the Boston University School of Medicine. ... cancer each year, many of which can be ...
Breaking Medicine News(10 mins):Health News:Dental SEO Analysis Launched by E-Dentists.com in Partnership with JD Media Surge 2Health News:AMTC’s Summer SHINE Event Coming to Orlando’s Luxurious Gaylord Palms July 2-7, 2013 2Health News:Amirsys AnatomyOne 2.0 Delivers Personalized Learning Plans 2Health News:Yahoo Commerce Head Joins Leadership at Dwell Media 2Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2
... more likely to die at birth , than other ... Mortality Rate currently ranks 42nd behind every other developed nation, including Cuba ... Cemetery is the home of BABYLAND, the final resting place for over ... the United States. , , NEW YORK, ...
... Dec. 16 Join STERIS Isomedix Services ... critical to success in,medical device sterilization ( http://www.isomedix.com/Markets/Medical/ ... on March 11, 2009, will provide,attendees the opportunity to ... more. , In ...
... Most significant effect was seen after 30 years of smoking, ... Adding to the long list of cancers caused by smoking, ... is higher in smokers, as is the risk of dying ... developing colorectal cancer by about 18 percent and the risk ...
... on the importance of colorectal-cancer screening , , ... for movie makers to enter Fred Hutchinson Cancer Research Center,s "Get ... spotlight on the importance of colorectal-cancer screening. All entries are due ... The contest is part of the Hutchinson Center,s ongoing awareness campaign ...
... A study released today in the Annals ... lower death rates from colorectal cancer, however, the procedure missed ... versus the left side. The study highlights the importance ... colonoscopy and that patients must take the bowel prep as ...
... CITY, Dec. 16 Can a high-energy diet pill really ... Even as car manufacturers, clothing makers and other retailers are ... economy, diet pill maker Zoller(R) Laboratories is reporting dramatically increased ... , (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LA52707 ...
Cached Medicine News:Health News:Birthing Project USA Unites to Reduce the African-American Infant Mortality Rate: Pilgrimage to Babyland 2Health News:STERIS Isomedix Services Offers Medical Device Sterilization Seminar 2Health News:Smoking Ups Colon Cancer Risk 2Health News:Smoking Ups Colon Cancer Risk 3Health News:A Month Left to Enter the 'Get Screened' Video Contest for a Chance to Win Up to $2,500 2Health News:ASGE urges patients to seek a qualified endoscopist before undergoing a colonoscopy 2Health News:ASGE urges patients to seek a qualified endoscopist before undergoing a colonoscopy 3Health News:Sales of Energy-Boosting Diet Pills Skyrocket as the Economy Falters 2
... The TOPCON ALE-3600 and ... assure perfectly fit lenses ... and with the convenience ... These lens edgers are ...
... a fast, precise patternless edge for a ... TOPCON ALE-X1. The latest advance in lens ... features and functions. High-speed processing, a diamond ... edges, precise three-dimensional frame tracing via the ...
Inquire...
Inquire...
Medicine Products: